Lyell Immunopharma, Inc.
General ticker "LYEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $246.0M (TTM average)
Lyell Immunopharma, Inc. follows the US Stock Market performance with the rate: 25.5%.
Estimated limits based on current volatility of 4.2%: low 13.06$, high 14.39$
Factors to consider:
- Total employees count: 300 (+33.9%) as of 2024
- Top business risk factors: High losses and need for capital, Regulatory and compliance, Limited operating history, Market competition, Manufacturing complexity
- Current price 19.6% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [17.45$, 49.24$]
- 2026-12-31 to 2027-12-31 estimated range: [9.70$, 29.34$]
Financial Metrics affecting the LYEL estimates:
- Negative: with PPE of -2.1 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 72.99 > 64.23
- Negative: Industry earnings per price (median), % of -13.64 <= 0
- Positive: Investing cash flow per share per price, % of 9.18 > -0.60
Short-term LYEL quotes
Long-term LYEL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.13MM | $0.06MM | $2.18MM |
| Operating Expenses | $247.14MM | $358.82MM | $271.58MM |
| Operating Income | $-247.01MM | $-358.75MM | $-269.40MM |
| Non-Operating Income | $12.38MM | $15.76MM | $-5.04MM |
| R&D Expense | $182.94MM | $171.60MM | $158.68MM |
| Income(Loss) | $-234.63MM | $-342.99MM | $-274.45MM |
| Net Income(Loss)* | $-234.63MM | $-342.99MM | $-274.45MM |
| Stockholders Equity | $654.95MM | $382.82MM | $248.20MM |
| Assets | $750.03MM | $490.86MM | $340.05MM |
| Operating Cash Flow | $-163.69MM | $-162.39MM | $-150.02MM |
| Capital expenditure | $2.69MM | $0.46MM | $0.78MM |
| Investing Cash Flow | $184.05MM | $122.42MM | $54.10MM |
| Financing Cash Flow | $1.74MM | $1.33MM | $50.41MM |
| Earnings Per Share** | $-18.70 | $-26.23 | $-16.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.